CADTH has received the following drug submission(s) and/or notice(s) of pending submission(s). If you are interested in providing patient input, please click on “Submit.” For information about the patient input process or for additional instructions, please see the Patient Input page of our website.
|Brand name||Generic name||Manufacturer||Indication(s)|
|Xultophy||insulin degludec + liraglutide||Novo Nordisk Canada Inc.||Diabetes mellitus, Type 2|
|Project Number||Call for patient input||Patient input deadline||Submit patient input|